Welcome to the international HTA database

Showing [17565 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Scottish Medicines Consortium (SMC)	Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
2021	Scottish Medicines Consortium (SMC)	Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
2021	Scottish Medicines Consortium (SMC)	Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
2020	Technology Assessment at SickKids (TASK)	Microcosting of whole genome sequencing (WGS) of trios in heterogeneous pediatric cardiac population
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	Rapid collaborative review on the current role of antibody tests for novel coronavirus SARS-CoV-2 in the management of the pandemic
2020	Norwegian Institute of Public Health (NIPH)	Safety, clinical effectiveness, predictive accuracy and cost effectiveness of blood based tests for women with suspected preeclampsia: a health technology assessment
2020	NIHR Health Services and Delivery Research programme	Stroke Sentinel Audit Programme: Investigating and Evaluating Stroke Therapy (SSNAPIEST)
2020	Norwegian Institute of Public Health (NIPH)	Intracoronary lithotripsy for the treatment of coronary artery disease: a health technology assessment
2020	NIHR Health Services and Delivery Research programme	An evaluation of a multifaceted intervention to reduce antimicrobial prescribing in care home residents [REducing Antimicrobials in Care Homes (REACH)]: a non-randomised feasibility study and process evaluation
2020	Norwegian Institute of Public Health (NIPH)	Disease modifying drugs for treatment of primary progressive multiple sclerosis: A health technology assessment
2020	NIHR Health Services and Delivery Research programme	UK Study of tendon Achilles Rehabilitation multicentre randomised clinical trial (UK STAR)
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Optimal use guide: pharmacological treatment of sexually transmitted and blood-borne infections ─ infections caused by chlamydia trachomatis and neisseria gonorrhoeae]
2020	NIHR Health Technology Assessment programme	Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation
2020	NIHR Health Services and Delivery Research programme	IMPlementation of A Relatives Toolkit (IMPART study): examining the critical success factors, barriers and facilitators to implementation of an online supported self-management intervention in the NHS
2020	NIHR Health Technology Assessment programme	Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Update PET/PET-CT evidence for need based planning in the area of oncology
2020	NIHR Health Technology Assessment programme	Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation
2020	NIHR Health Technology Assessment programme	Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Proton and carbon ion therapy - an update on indications
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Endovascular treatment of varicose veins by radiofrequency ablation or cyanoacrylate closure]
2020	NIHR Health Technology Assessment programme	Oral splints for patients with temporomandibular disorders or bruxism: a systematic review and economic evaluation
2020	NIHR Health Technology Assessment programme	Interventions to reduce the risk of surgically transmitted Creutzfeldt–Jakob disease: a cost-effective modelling review
2020	Swiss Federal Office of Public Health (FOPH)	Olmesartan Mono- and Combination Therapies in Patients with Essential Hypertension
2020	Swiss Federal Office of Public Health (FOPH)	Treatment of non-erosive gastroesophageal reflux disease patients with proton pump inhibitors
2020	Swiss Federal Office of Public Health (FOPH)	Chondroitin Sulfate in Osteoarthritis
2020	Swiss Federal Office of Public Health (FOPH)	Iron Therapy for Iron Deficiency without Anemia
2020	Health Technology Wales (HTW)	Autologous haematopoietic stem cell transplantation for previously treated, relapsing-remitting multiple sclerosis
2020	Health Technology Wales (HTW)	Pre-operative cardiopulmonary exercise testing for people in whom major abdominal surgery is planned
2020	Health Technology Wales (HTW)	Rapid antigen detecting tests for diagnosing group A streptococcal infections in the community pharmacy setting
2020	Health Technology Wales (HTW)	Transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis who are at intermediate surgical risk
2020	Health Technology Wales (HTW)	Point of care haemolysis detection in blood samples that may be deemed unfit for laboratory analysis
2020	NIHR Health Technology Assessment programme	Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of the left ventricular assist device (LVAD) as destination therapy in paediatric patients]
2020	NIHR Health Services and Delivery Research programme	The effects of interoperable information technology networks on patient safety: a realist synthesis
2020	European Network for Health Technology Assessment (EUnetHTA)	Rolling Collaborative Review COVID-19 - Lopinavir + Ritonavir
2020	NIHR Health Services and Delivery Research programme	Social norms interventions to change clinical behaviour in health workers: a systematic review and meta-analysis
2020	Belgian Health Care Knowledge Centre (KCE)	Polyvalent immunoglobulins – Part 2: use in Belgium
2020	Norwegian Institute of Public Health (NIPH)	[Intermittent pneumatic compression for preventing deep vein thrombosis in acute stroke, a health technology assessment]
2020	Norwegian Institute of Public Health (NIPH)	[Effectiveness of microwave thermotherapy (TUMT) compared to transurethral resection of the prostate (TURP) for benign prostatic hyperplasia]
2020	NIHR Health Services and Delivery Research programme	Variations in the organisation of Early Pregnancy Assessment Units (EPAUs) in the UK and their effects on clinical, service and patient-centred outcomes (VESPA)
2020	NIHR Health Technology Assessment programme	Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation
2020	National Committee for Technology Incorporation (CONITEC)	[Dolutegravir for the treatment of pregnant women living with HIV]
2020	National Committee for Technology Incorporation (CONITEC)	[Baricitinib (Olumiant) for patients with moderate to severe active rheumatoid arthritis]
2020	NIHR Health Technology Assessment programme	A systematic review of psychological interventions to improve motivation for self-management in people with type 1 and type 2 diabetes
2020	National Committee for Technology Incorporation (CONITEC)	[Mirabegron for the treatment of storage dysfunction in patients with neurogenic bladder]
2020	NIHR Health Services and Delivery Research programme	Using co-production to improve patient carer and staff experiences in health care organizations: a multi-centre, mixed methods evaluation in inpatient stroke units (CREATE)
2020	National Committee for Technology Incorporation (CONITEC)	[Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]
2020	National Committee for Technology Incorporation (CONITEC)	[Photodynamic therapy for non-melanoma skin cancer]
2020	National Committee for Technology Incorporation (CONITEC)	[Newborn screening for congenital toxoplasmosis]
2020	NIHR Public Health Research (PHR) programme	A woman-centred, tailored SMS-delivered multi-component intervention for weight loss and maintenance of weight loss in the postpartum period: intervention adaptation and pilot RCT
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020	National Committee for Technology Incorporation (CONITEC)	[Riociguat for inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension after surgical treatment]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Orlistat for weight loss in overweight or obese patients]
2020	NIHR Public Health Research (PHR) programme	A two arm feasibility trial of lifestyle information and Slimming World groups to promote weight management and positive lifestyle behaviour in postnatal women from an ethnically diverse inner city population
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Sibutramine for the treatment of obese patients]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Venetoclax (chronic lymphocytic leukaemia) - Addendum to Commission A20-39]
2020	National Committee for Technology Incorporation (CONITEC)	[Empagliflozin and dapagliflozin for the treatment of type 2 diabetes mellitus]
2020	NIHR Health Services and Delivery Research programme	Evaluating the use of patient experience data to improve the quality of inpatient mental health care
2020	NIHR Health Technology Assessment programme	Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Osilodrostat (endogenous Cushing syndrome) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Rifapentine plus isoniazid for treatment of latent mycobacterium tuberculosis infection (LTBI)]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Addendum to Commission A20-43]
2020	National Committee for Technology Incorporation (CONITEC)	[Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020	National Committee for Technology Incorporation (CONITEC)	[Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2020	NIHR Public Health Research (PHR) programme	The effectiveness of promotional campaigns associated with revised UK drinking guidelines: a prospective evaluation
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Onasemnogene abeparvovec (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code] Book V
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Personal frequency modulation system for hearing-impaired students at any age and at any academic level]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Givosiran (acute hepatic porphyria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Cytoreductive surgery (peritonectomy) with hyperthermic intraperitoneal chemotherapy (HIPEC)]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Development of scientific concepts for the generation of routine practice data and their analysis for the benefit assessment of drugs according to §35a Social Code Book V – rapid report]
2020	National Committee for Technology Incorporation (CONITEC)	[Ruxolitinib for the treatment of patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Urinary proteome analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension. Update of Commission D13-01. - Rapid Report]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Risk assessments and structured care interventions for prevention of foot ulceration in diabetes: development and validation of a prognostic model
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2020	NIHR Health Technology Assessment programme	The Namaste Care intervention to improve the quality of dying for people with advanced dementia living in care homes: a realist review and feasibility study for a cluster randomised controlled trial
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	Ceftolozane/tazobactam (acute pyelonephritis) - Benefit assessment according to §35a Social Code Book V
2020	NIHR Health Technology Assessment programme	Non-contact infrared thermometers for measuring body temperature in acutely ill children: a method comparison study
2020	NIHR Health Services and Delivery Research programme	Effects of increased distance to urgent and emergency care facilities resulting from health services reconfiguration: a systematic review
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cobicistat (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	Ceftolozane/tazobactam (hospital-acquired pneumonia) - Benefit assessment according to §35a Social Code Book V
2020	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical Practice Guidelines on the diagnosis and treatment of non-serious blunt chest trauma]
2020	NIHR Health Technology Assessment programme	CARer-ADministration of as-needed sub-cutaneous medication for breakthrough symptoms in home-based dying patients: a UK study (CARiAD)
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Rapid review: alternatives to timolol for the treatment of glaucoma]
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Comparative results of the different screening strategies used for T21, T18 and T13: adaptation of the EUnetHTA assessment]
2020	NIHR Health Services and Delivery Research programme	Factors influencing the utilisation of free-standing and alongside midwifery units in England: a mixed methods research study
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Update 12 months follow-up: Nusinersen in spinal muscular atrophy ("late onset") in children and adolescents ≥ 6 years
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Leadless pacemaker for right ventricle pacing (Update 2020)
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS. Update 2020
2020	Ontario Health	Transcatheter Aortic Valve Implantation in Patients With Severe, Symptomatic Aortic Valve Stenosis at Intermediate Surgical Risk: A Health Technology Assessment